Floatz logo

Blinatumomab

Recurrent Mediastinal Lymphoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Recurrent Mediastinal Lymphoma cohort.

Asset / SponsorPhaseRating
Ibrutinib
Kami Maddocks
Phase 1CC
Pembrolizumab
Kami Maddocks
Phase 1CC
cc-5013
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

Blinatumomab is also rated in:

precursor B-cell acute lymphoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
72 / 100
View asset →
Precursor B-Cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →